Supercharge Your Innovation With Domain-Expert AI Agents!

Preparation method of BCL-2 inhibitor venetoclax

A technology for BCL-2 and inhibitors, which is applied in the field of preparation of BCL-2 inhibitor-Vitekla, can solve the problems of unsuitable large-scale industrial production and preparation, limited drug application, poor operability, etc., and achieves simple and easy reaction, Enhanced operability and short steps

Active Publication Date: 2020-03-13
NANTONG CHANGYOO PHARMATECH CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the Vitekla synthesis process in the prior art has the disadvantages of complex routes, poor operability, and not suitable for large-scale industrial production, which limits the application of this type of drug to a certain extent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of BCL-2 inhibitor venetoclax
  • Preparation method of BCL-2 inhibitor venetoclax

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Step 1, preparation of V1:

[0031] At room temperature, VM1 (18.1g, 105mmol, 1.05eq), 1-p-toluenesulfonyl-5-hydroxyl-7-azaindole (28.8g, 100mmol, 1.0eq), potassium carbonate ( 27.6g, 200mmol, 2.0eq) and 300mL dimethyl sulfoxide, stirred, heated to 95-100°C for reaction, and TLC monitored the reaction. After the reaction is complete, cool down to room temperature, add 1000mL of water, stir, extract with isopropyl acetate (500mL×3), combine the organic phases, wash with saturated brine (300mL×1), dry over anhydrous sodium sulfate, suction filter, and the filtrate Concentrate under reduced pressure to dryness, add 350mL of n-heptane to the residual liquid for slurry, filter with suction, and dry to obtain 40.1g of solid product V1 with a yield of 91%.

[0032] Step 2, preparation of V2:

[0033] Add intermediate V1 (40.1g, 91mmol, 1.0eq), Boc piperazine (18.6g, 100mmol, 1.1eq), potassium carbonate (25.1g, 182mmol, 2.0eq) and 500mL tetrahydrofuran in a 1000mL reaction fl...

Embodiment 2

[0043] Step 1, preparation of V1:

[0044] At room temperature, VM1 (10.3g, 60mmol, 1.2eq), 2-nitrobenzenesulfonyl-5-hydroxyl-7-azaindole (16g, 50mmol, 1.0eq), potassium phosphate ( 21.2g, 100mmol, 2.0eq) and 200mL N,N-dimethylformamide, stirred, heated up to 95-100°C for reaction, and TLC monitored the reaction. After the reaction is complete, cool down to room temperature, add 500 mL of water, stir, extract with tert-butyl acetate (200 mL×3), combine the organic phases, wash with saturated brine (200 mL×1), dry over anhydrous sodium sulfate, suction filter, and the filtrate Concentrate under reduced pressure to dryness, add 200 mL of n-hexane to the residual liquid to make a slurry, filter with suction, and dry to obtain 21.3 g of solid product V1 with a yield of 90%.

[0045] Step 2, preparation of V2:

[0046] Add intermediate V1 (21.3g, 45mmol, 1.0eq), Boc piperazine (12.6g, 68mmol, 1.5eq), triethylamine (13.6g, 135mmol, 3.0eq) and 300mL acetonitrile in 500mL reaction f...

Embodiment 3

[0056] Step 1, preparation of V1:

[0057] At room temperature, VM1 (19.4g, 113mmol, 1.5eq), 4-nitrobenzenesulfonyl-5-hydroxyl-7-azaindole (24g, 75mmol, 1.0eq), potassium phosphate ( 23.9g, 225mmol, 3.0eq) and 300mL dimethyl sulfoxide, stirred, heated to 95-100°C for reaction, TLC monitored the reaction. After the reaction is complete, cool down to room temperature, add 600 mL of water, stir, extract with tert-butyl acetate (300 mL×3), combine the organic phases, wash with saturated brine (300 mL×1), dry over anhydrous sodium sulfate, suction filter, and the filtrate Concentrate under reduced pressure to dryness, add 300mL of n-hexane to the residual liquid to make a slurry, filter with suction, and dry to obtain 31.2g of solid product V1 with a yield of 88%.

[0058] Step 2, preparation of V2:

[0059] In 500mL reaction flask, add intermediate V1 (31.2g, 66mmol, 1.0eq), Boc piperazine (22.1g, 119mmol, 1.8eq), DIPEA (25.5g, 198mmol, 3.0eq) and 300mL tetrahydrofuran, stir, be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of a BCL-2 inhibitor venetoclax. The method mainly comprises the following six steps: 1) VM1 and VM2 used as reaction starting materials undergo a dockingreaction under the catalytic action of an alkali to prepare an intermediate V1; 2) the intermediate V1 reacts with Boc piperazine under the catalytic action of the alkali to prepare an intermediate V2; 3) Boc protection is removed from the intermediate V2 under the action of an acid reagent to prepare an intermediate V3; 4) the intermediates V3 and VM3 are heated to react to form a Schiff base, and the Schiff base is converted into secondary amine under the action of a reducing agent to prepare an intermediate V4; 5) the intermediate V4 reacts with the intermediate VM4 under the action of a condensing agent to prepare an amide compound intermediate V5; and 6) a phenylsulfonyl protecting group is removed from the intermediate V5 under the catalysis of a catalyst to obtain the final productvenetoclax. Compared with the prior art, the preparation method has the advantages of short steps, simple and feasible reaction, and suitableness for large-scale industrial production.

Description

technical field [0001] The invention relates to the field of drug synthesis, in particular to a preparation method of BCL-2 inhibitor-Vitekla. Background technique [0002] Venetoclax is a breakthrough anticancer drug jointly developed by Abbvie and Roche. It was the first drug approved by the US Food and Drug Administration (FDA) on April 11, 2016. A B-cell lymphoma-2 gene inhibitor (BCL-2), which is mainly used for patients with chronic lymphocytic leukemia (CLL) with 17p gene deletion and who have received at least one drug therapy. [0003] BCL-2 family members are mainly involved in the regulation of mitochondrial outer membrane, such as Bad, Bax, etc. can promote apoptosis, BCL-2, MCL-1, etc. can inhibit apoptosis. The overexpression of BCL-2 family inhibits apoptosis proteins often enables tumor cells to escape apoptosis and develop resistance to a variety of antitumor drugs. Vitekla is a specific small molecule inhibitor of Bcl-2, which can specifically inhibit Bcl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04
CPCC07D471/04Y02P20/55
Inventor 李泽标陈丹吴洪当徐晓红林燕峰
Owner NANTONG CHANGYOO PHARMATECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com